Lowest corona cases reported in India in 1 day since March 2020
The process of getting infected with corona has not stopped all over the world, but there has definitely been a significant decrease in its cases. After report of 36 new cases of corona virus infection in India in one day, the number of people infected so far in the country has increased to 4,49,93,579. This is the lowest number of new cases reported in a day after March 2020. At the same time, the number of patients under treatment has come down to 1,844.
According to the updated data released by the Union Health Ministry at 8 am on Tuesday, the total number of people who lost their lives due to infection in the country is 5,31,897. According to the latest data, the national rate of recovery of patients in India is 98.81 percent. So far, a total of 4,44,59,838 people have become infection free in the country, while the death rate from Covid-19 is 1.18 percent. According to the website of the Ministry of Health, so far 2,20,67,34,611 doses of anti-Covid-19 vaccines have been administered under the nationwide vaccination campaign in India.
In India, on 7th August 2020, the number of corona virus infected had crossed 20 lakhs, on 23rd August 2020 it crossed 30 lakhs and on 5th September 2020 it crossed 40 lakhs. The total cases of infection had crossed 50 lakhs on 16 September 2020
On 19 December 2020, these cases had crossed one crore in the country. On May 4, 2021, the number of infected had crossed two crore and on June 23, 2021, it crossed three crore. Last year, on January 25, the total cases of infection had crossed four crores.
Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology
The Department of Biotechnology (DBT) has announced that the Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology by Gennova Biopharmaceuticals Ltd. and supported under the Mission COVID Suraksha, implemented by Biotechnology Industry Research Assistance Council (BIRAC), has got a nod from the office of the Drug Control General of India (DCGI) for Emergency Use Authorization (EUA).
DBT has facilitated establishing Gennova’s mRNA-based next-generation vaccine manufacturing for developingthe platform technology from proof of concept till Phase I clinical trial of the prototype mRNA-based vaccine developed against the Wuhan strain. The project was further supported under the’Mission COVID Suraksha. The Indian COVID-19 Vaccine Development Mission’ by DBT’s dedicated Mission Implementation Unit at Biotechnology Industry Research Assistance Council (BIRAC), for further clinical development and Scale up of the prototype vaccine, which received EUA on 29th June 2022. The platform technology developed was used to develop an Omicron-specific booster vaccine for COVID-19.
GEMCOVAC®-OM is an Omicron-specific mRNA-based Booster vaccine developed using the indigenous platform technology by Gennova in collaboration with DBT. Like the prototype vaccine, GEMCOVAC®-OM is a thermostable vaccine, which does not require ultra-cold chain infrastructure used for other approved mRNA-based vaccines, making it easy for deployment pan India. It is delivered intra-dermally using a needle-free injection device system. When administered intradermally in participants as a booster,it generated significantly higher immune responses.The clinical outcome demonstrates the need for variant-specific vaccines for desired immune response.
